HMGB1 deficiency most commonly occurred in pheochromocytoma (90.0%), seminoma (72.4%), gastrointestinal stromal tumor (28.6%), adrenal cortical carcinoma (25.0%), Hodgkin’s lymphoma (25.0%), Leydig cell tumor of the testis (16.7%), prostatic adenocarcinoma (8.9–16.4%), renal cell tumors (8.4–16.2%), yolk sac tumor of the testis (15.4%), paraganglioma (12.5%), neuroendocrine tumor of the lung (11.1%), adrenocortical adenoma (10.8%), epithelioid mesothelioma (10.7%), and in clear cell carcinoma of the ovary (9.8%). Here, HMGB1 is linked to adrenal cortex carcinoma.